-
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality Br. J. Cancer (IF 8.8) Pub Date : 2024-03-18 Anya Burton, Jennifer Wilburn, Robert J. Driver, David Wallace, Sean McPhail, Tim J. S. Cross, Ian A. Rowe, Aileen Marshall
-
Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-15 Yiwen Zhang, Konrad H. Stopsack, Kana Wu, Mingyang Song, Lorelei A. Mucci, Edward Giovannucci
Background Multivitamin use is common among cancer patients. Whether post-diagnostic multivitamin supplementation is beneficial for prostate cancer survival is largely unknown, and some evidence even suggests potential harm. Methods We prospectively assessed post-diagnostic multivitamin use in relation to prostate cancer survival among 4756 men with nonmetastatic prostate cancer at diagnosis in the
-
Transforming post pandemic cancer services Br. J. Cancer (IF 8.8) Pub Date : 2024-03-15 Thomas Round, Lakshman Sethuraman, Mark Ashworth, Arnie Purushotham
-
Functional proteomics of colon cancer Consensus Molecular Subtypes Br. J. Cancer (IF 8.8) Pub Date : 2024-03-14 Jaime Feliu, Angelo Gámez-Pozo, Daniel Martínez-Pérez, Pablo Pérez-Wert, Daniel Matamala-Luengo, David Viñal, Laura Kunz, Rocío López- Vacas, Antje Dittmann, Nuria Rodríguez-Salas, Ana Custodio, Juan Ángel Fresno Vara, Lucía Trilla-Fuertes
-
Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation Br. J. Cancer (IF 8.8) Pub Date : 2024-03-13 Xiaomeng Zhang, Yazhou He, Xue Li, Rasha Shraim, Wei Xu, Lijuan Wang, Susan M. Farrington, Harry Campbell, Maria Timofeeva, Lina Zgaga, Peter Vaughan-Shaw, Evropi Theodoratou, Malcolm G. Dunlop
-
Single-cell RNA sequencing analysis of vestibular schwannoma reveals functionally distinct macrophage subsets Br. J. Cancer (IF 8.8) Pub Date : 2024-03-13 Paramita Baruah, Christopher Mahony, Jennifer L. Marshall, Charlotte G. Smith, Peter Monksfield, Richard I. Irving, Ingrid E. Dumitriu, Christopher D. Buckley, Adam P. Croft
-
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial Br. J. Cancer (IF 8.8) Pub Date : 2024-03-12 Jinlin Cai, Kaixin Lin, Tongfeng Luo, Jingrong Weng, Haotian Liu, Ze Yuan, Zixiao Wan, Junyi Han, Jinxin Lin, Xiaoxia Liu, Xiaolin Wang, Meijin Huang, Yanxin Luo, Huichuan Yu
-
RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation Br. J. Cancer (IF 8.8) Pub Date : 2024-03-11 Yun-Suhk Suh, Jieun Lee, Joshy George, Donghyeok Seol, Kyoungyun Jeong, Seung-Young Oh, Chanmi Bang, Yukyung Jun, Seong-Ho Kong, Hyuk-Joon Lee, Jong-Il Kim, Woo Ho Kim, Han-Kwang Yang, Charles Lee
-
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells Br. J. Cancer (IF 8.8) Pub Date : 2024-03-11 Anxo Rio-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A. Mateos-Gómez, Marina I. Schlaepfer, Laura del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
-
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme Br. J. Cancer (IF 8.8) Pub Date : 2024-03-11 Daniëlle E. ten Velde, Lucien E. M. Duijm, Maurice J. C. van der Sangen, Robert-Jan Schipper, Vivianne C. G. Tjan-Heijnen, Willem Vreuls, Luc J. A. Strobbe, Adri C. Voogd
-
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions Br. J. Cancer (IF 8.8) Pub Date : 2024-03-09 M. Medrano, M. Contreras, T. Caballero-Velázquez, L. Martínez, J. A. Bejarano-García, R. Calderón-Ruiz, C. B. García-Calderón, I. V. Rosado, J. A. Pérez-Simón
-
Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis Br. J. Cancer (IF 8.8) Pub Date : 2024-03-09 Masataka Yokode, Masahiro Shiokawa, Hisato Kawakami, Takeshi Kuwada, Yoshihiro Nishikawa, Yuya Muramoto, Hiroki Kitamoto, Makoto Okabe, Hajime Yamazaki, Norihiro Okamoto, Toshihiro Morita, Kazuya Ohno, Risa Nakanishi, Ikuhisa Takimoto, Muneji Yasuda, Koki Chikugo, Shimpei Matsumoto, Hiroyuki Yoshida, Sakiko Ota, Takeharu Nakamura, Hirokazu Okada, Tomonori Hirano, Nobuyuki Kakiuchi, Tomoaki Matsumori
-
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis Br. J. Cancer (IF 8.8) Pub Date : 2024-03-09 Zhaochen Ning, Keyan Liu, Hui Zhang, Guanjun Dong, Xiaotong Wang, Huabao Xiong
-
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis Br. J. Cancer (IF 8.8) Pub Date : 2024-03-08 Li-Qiang Deng, Chuan-Jian Shi, Shu-Ting Zhou, Wei-Qiang Zeng, Yan-Fang Xian, Yu-Yan Wang, Wei-Ming Fu, Han-Li Lin, Wei Liu, Jin-Fang Zhang
-
Pirfenidone alleviates fibrosis by acting on tumour–stroma interplay in pancreatic cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-07 Yalan Lei, Jin Xu, Mingming Xiao, Di Wu, He Xu, Jing Yang, Xiaoqi Mao, Haoqi Pan, Xianjun Yu, Si Shi
-
PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Shota Takihira, Daisuke Yamada, Tatsunori Osone, Tomoka Takao, Masakiyo Sakaguchi, Michiyuki Hakozaki, Takuto Itano, Eiji Nakata, Tomohiro Fujiwara, Toshiyuki Kunisada, Toshifumi Ozaki, Takeshi Takarada
-
A metabolic map and artificial intelligence-aided identification of nasopharyngeal carcinoma via a single-cell Raman platform Br. J. Cancer (IF 8.8) Pub Date : 2024-03-07 Jiabao Xu, Dayang Chen, Wei Wu, Xiang Ji, Xiaowen Dou, Xiaojuan Gao, Jian Li, Xiuming Zhang, Wei E. Huang, Dan Xiong
-
Shifting the paradigm in the management of early prostate cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Vincent Gnanapragasam
Outcomes from active surveillance have clearly shown that it is the optimal method of managing many early prostate cancers. Yet, clinician training and healthcare systems are still primarily focused on the “need to treat”. This comment explores the challenges and resource issues in future implementation of high-quality surveillance programmes.
-
Early onset pancreatic cancer—exploring contemporary treatment and outcomes using real-world data Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Shehara Mendis, Lara Lipton, Yat Hang To, Sumitra Ananda, Michael Michael, Sue-Anne McLachlan, Benjamin Thomson, Benjamin Loveday, Brett Knowles, Adrian Fox, Mehrdad Nikfarjam, Val Usatoff, Julia Shapiro, Kate Clarke, Sharon Pattison, Cheng Ean Chee, Rob Zielinski, Rachel Wong, Peter Gibbs, Belinda Lee
-
Risk and adverse clinical outcomes of thrombocytopenia among patients with solid tumors—a Danish population-based cohort study Br. J. Cancer (IF 8.8) Pub Date : 2024-03-06 Kasper Adelborg, Katalin Veres, Erzsébet Horváth-Puhó, Mary Clouser, Hossam Saad, Henrik Toft Sørensen
-
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma Br. J. Cancer (IF 8.8) Pub Date : 2024-03-04 Yusuke Matoba, Dominique T. Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim, Shaan Kumar, Mengyao Xu, Xingping Qin, Lauren J Ray, Kyle M. Devins, Raj Kumar, Artem Kononenko, Eric Eisenhauer, Irva E. Veillard, Wataru Yamagami, Sarah J. Hill, Kristopher A. Sarosiek, Oladapo O. Yeku, David R. Spriggs, Bo R. Rueda
-
A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp Br. J. Cancer (IF 8.8) Pub Date : 2024-03-01 Laetitia Herman, Angélique Amo, Berangère Legois, Caterina Di Carlo, Reiner A. Veitia, Anne-Laure Todeschini
-
Redefining cancer research for therapeutic breakthroughs Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Arseniy E. Yuzhalin
-
Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Mark P. Little, Jim Z. Mai, Michelle Fang, Pavel Chernyavskiy, Victoria Kennerley, Elizabeth K. Cahoon, Myles G. Cockburn, Gerald M. Kendall, Michael G. Kimlin
-
Single-cell RNA sequencing reveals myeloid and T cell co-stimulation mediated by IL-7 anti-cancer immunotherapy Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Hye Hyeon Eum, Dasom Jeong, Nayoung Kim, Areum Jo, Minsu Na, Huiram Kang, Yourae Hong, Jin-Sun Kong, Gi Heon Jeong, Seung-Ah Yoo, Hae-Ock Lee
-
Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels Br. J. Cancer (IF 8.8) Pub Date : 2024-02-29 Mustafa B. A. Djamgoz
Background Multi-faceted evidence from a range of cancers suggests strongly that de novo expression of voltage-gated sodium channels (VGSCs) plays a significant role in driving cancer cell invasiveness. Under hypoxic conditions, common to growing tumours, VGSCs develop a persistent current (INaP) which can be blocked selectively by ranolazine. Methods Several different carcinomas were examined. We
-
Comment on “Dexamethasone-sparing on days 2–4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)” Br. J. Cancer (IF 8.8) Pub Date : 2024-02-26 Luigi Celio, Andrea Antonuzzo, Matti S. Aapro
Minatogawa et al. [1] should be commended for conducting this important trial. Antiemetic guidelines devised from the major international organizations recommend now olanzapine as a fixed part of a four-drug prophylactic regimen in the setting of highly emetogenic chemotherapy (HEC) [2, 3]. In light of this, it is clinically relevant that a four-drug regimen containing olanzapine, palonosetron, a neurokinin-1
-
Risk of cancer and serious disease in Danish patients with urgent referral for serious non-specific symptoms and signs of cancer in Funen 2014–2021 Br. J. Cancer (IF 8.8) Pub Date : 2024-02-26 Rasmus Birkholm Grønnemose, Per Syrak Hansen, Søren Worsøe Laursen, Oke Gerke, Jakob Kjellberg, Jesper Lykkegaard, Clara Thye-Rønn, Poul Flemming Høilund-Carlsen, Peter Thye-Rønn
-
A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study Br. J. Cancer (IF 8.8) Pub Date : 2024-02-22 Qinran Liu, Yiwen Zhang, Jane B. Vaselkiv, Lorelei A. Mucci, Edward L. Giovannucci, Elizabeth A. Platz, Siobhan Sutcliffe
Background Previous studies have observed inconsistent associations between birth weight and aggressive prostate cancer risk. This study aimed to prospectively analyse this association in the Health Professionals Follow-up Study (HPFS). Methods Birth weight was self-reported in 1994, and prostate cancer diagnoses were assessed biennially through January 2017 and confirmed by medical record review.
-
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database Br. J. Cancer (IF 8.8) Pub Date : 2024-02-24 C. S. Karapetis, H. Liu, M. J. Sorich, L. D. Pederson, E. Van Cutsem, T. Maughan, J. Y. Douillard, C. J. O’Callaghan, D. Jonker, C. Bokemeyer, A. Sobrero, C. Cremolini, B. Chibaudel, J. Zalcberg, R. Adams, M. Buyse, M. Peeters, T. Yoshino, A. de Gramont, Q. Shi
-
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-02-23 Cath Eberlein, Stuart C. Williamson, Lorna Hopcroft, Susana Ros, Jennifer I. Moss, James Kerr, Wytske M. van Weerden, Elza C. de Bruin, Shanade Dunn, Brandon Willis, Sarah J. Ross, Claire Rooney, Simon T. Barry
-
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro Br. J. Cancer (IF 8.8) Pub Date : 2024-02-23 Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D. Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
-
Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity Br. J. Cancer (IF 8.8) Pub Date : 2024-02-22 Batel Blechter, Jason Y. Y. Wong, Li-Hsin Chien, Kouya Shiraishi, Xiao-Ou Shu, Qiuyin Cai, Wei Zheng, Bu-Tian Ji, Wei Hu, Mohammad L. Rahman, Hsin-Fang Jiang, Fang-Yu Tsai, Wen-Yi Huang, Yu-Tang Gao, Xijing Han, Mark D. Steinwandel, Gong Yang, Yihe G. Daida, Su-Ying Liang, Scarlett L. Gomez, Mindy C. DeRouen, W. Ryan Diver, Ananya G. Reddy, Alpa V. Patel, Loïc Le Marchand, Christopher Haiman, Takashi
Background We characterized age at diagnosis and estimated sex differences for lung cancer and its histological subtypes among individuals who never smoke. Methods We analyzed the distribution of age at lung cancer diagnosis in 33,793 individuals across 8 cohort studies and two national registries from East Asia, the United States (US) and the United Kingdom (UK). Student’s t-tests were used to assess
-
CAnceR IN PreGnancy (CARING) – a retrospective study of cancer diagnosed during pregnancy in the United Kingdom Br. J. Cancer (IF 8.8) Pub Date : 2024-02-21 M. A. Baxter, M. Denholm, S. J. Kingdon, S. Kathirgamakarthigeyan, S. Parikh, R. Shakir, R. Johnson, H. Martin, M. Walton, W. Yao, A. Swan, C. Samuelson, X. Ren, A. Cooper, H-L Gray, S. Clifton, J. Ball, G. Gullick, M. Anderson, L. Dodd, H. Hayhurst, M. Salama, R. Shotton, F. Britton, T. Christodoulou, A. Abdul-Hamid, A. Eichholz, R. M. Evans, P. Wallroth, F. Gibson, K. Poole, M. Rowe, J. Harris
-
Comment on “Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases” Br. J. Cancer (IF 8.8) Pub Date : 2024-02-20 Tianfei Yu, Changfei Yang, Ming Li
We read with interest the original paper by Zhu et al. [1], in which they analyzed 2489 breast cancers patients undergoing neoadjuvant therapy (NAT) from 2009 to 2020. Human epidermal growth factor receptor-2 (HER2)-low status, defined as immunohistochemical (IHC) expression 1+/2+ and fluorescence in situ hybridization (FISH) negative, was observed in 41.1% of patients. HER2-low patients had higher
-
Stratifying ICIs-responsive tumor microenvironment in HCC: from parsing out immune-hypoxic crosstalk to clinically applicable MRI-radiomics models Br. J. Cancer (IF 8.8) Pub Date : 2024-02-14 Li-Na Song, Biao Wang, Jia-Liang Cai, Pei-Ling Zhang, Shi-Ping Chen, Zheng-Jun Zhou, Zhi Dai
-
Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-02-14 Xue Song, Chen Fang, Yan Dai, Yang Sun, Chang Qiu, Xiaojie Lin, Rui Xu
-
Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden Br. J. Cancer (IF 8.8) Pub Date : 2024-02-12 Guoqiao Zheng, Mette Tuxen Faber, Jiangrong Wang, Louise Baandrup, Rasmus Hertzum-Larsen, Karin Sundström, Susanne K. Kjær
-
HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study Br. J. Cancer (IF 8.8) Pub Date : 2024-02-12 Alessandra Anna Prete, Valentina Angerilli, Francesca Bergamo, Valentina Vettore, Chiara De Toni, Rossana Intini, Krisida Cerma, Gianmarco Ricagno, Riccardo Cerantola, Eleonora Perissinotto, Antonio De Rosa, Carlotta Ceccon, Jessica Gasparello, Luca Denaro, Alberto D’Amico, Franco Chioffi, Elena Carcea, Matteo Fassan, Sara Lonardi
-
ABCC4 suppresses glioblastoma progression and recurrence by restraining cGMP-PKG signalling Br. J. Cancer (IF 8.8) Pub Date : 2024-02-12 Jung-Ying Chiang, Sung-Tai Wei, Huan-Jui Chang, Der-Cherng Chen, Hwai-Lee Wang, Fu-Ju Lei, Kai-Yu Wei, Yen‐Chih Huang, Chi-Chung Wang, Chia-Hung Hsieh
-
IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells Br. J. Cancer (IF 8.8) Pub Date : 2024-02-12 Kai Zhang, Wenhao Hu, Feng Li, Chunli Wen, Lingxiao Zhou, Lei Zhang, Jingyao Lian, Shasha Liu, Shumin Wang, Yi Zhang
-
Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE Br. J. Cancer (IF 8.8) Pub Date : 2024-02-12 Fei Shen, Guanglong Jiang, Santosh Philips, Erica Cantor, Laura Gardner, Gloria Xue, Geneva Cunningham, Nawal Kassem, Anne O’Neill, David Cameron, Thomas M. Suter, Kathy D. Miller, George W. Sledge, Bryan P. Schneider
-
Unraveling the impact of cancer-associated fibroblasts on hypovascular pancreatic neuroendocrine tumors Br. J. Cancer (IF 8.8) Pub Date : 2024-02-10 Ting-Yu Lai, Tsai-Chen Chiang, Chih-Yuan Lee, Ting-Chun Kuo, Chien-Hui Wu, Yi-Ing Chen, Chun-Mei Hu, Manjit Maskey, Shiue-Cheng Tang, Yung-Ming Jeng, Yu-Wen Tien, Eva Y.-H. P. Lee, Wen-Hwa Lee
-
Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas Br. J. Cancer (IF 8.8) Pub Date : 2024-02-10 Dorottya Moldvai, Dániel Sztankovics, Titanilla Dankó, Enikő Vetlényi, Gábor Petővári, Ágnes Márk, Attila Patonai, Gyula Végső, László Piros, Ádám Hosszú, Judit Pápay, Ildikó Krencz, Anna Sebestyén
-
Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy Br. J. Cancer (IF 8.8) Pub Date : 2024-02-10 Hai-Shan Ye, Dan Zhou, Hong Li, Jin Lv, Hui-Qi Huang, Jia-Jun She, Jun-Hua Nie, Ting-Ting Li, Meng-Di Lu, Bo-Le Du, Shu-Qing Yang, Pei-Xian Chen, Sheng Li, Guo-Lin Ye, Wei Luo, Jia Liu
-
Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-02-08 Lu Zhang, Ruiyun Zhang, Di Jin, Tianxiang Zhang, Akezhouli Shahatiaili, Jingyu Zang, Lu Wang, Yuanchun Pu, Guanglei Zhuang, Haige Chen, Jinhai Fan
-
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication Br. J. Cancer (IF 8.8) Pub Date : 2024-02-09 Nanna Monjé, Mihnea P. Dragomir, Bruno V. Sinn, Inga Hoffmann, Anuar Makhmut, Tincy Simon, Catarina A. Kunze, Jana Ihlow, Wolfgang D. Schmitt, Jonathan Pohl, Iris Piwonski, Sofya Marchenko, Carlotta Keunecke, Teodor G. Calina, Francesca Tiso, Hagen Kulbe, Caroline Kreuzinger, Dan Cacsire Castillo-Tong, Jalid Sehouli, Elena I. Braicu, Carsten Denkert, Silvia Darb-Esfahani, Kirsten Kübler, David Capper
-
Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study Br. J. Cancer (IF 8.8) Pub Date : 2024-02-08 Renata Abrahão, Ann Brunson, Kathryn J. Ruddy, Qian Li, Judy Li, Mabel M. Ryder, Jessica Chubak, Hazel B. Nichols, Candice A. M. Sauder, Marlaine F. Gray, Erin E. Hahn, Ted Wun, Theresa H. M. Keegan
-
Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study Br. J. Cancer (IF 8.8) Pub Date : 2024-02-07 Takuro Saito, Yukinori Kurokawa, Kazumasa Fujitani, Ryohei Kawabata, Atsushi Takeno, Jota Mikami, Shunji Endo, Jin Matsuyama, Yusuke Akamaru, Masashi Hirota, Kentaro Kishi, Shinya Urakawa, Kei Yamamoto, Koji Tanaka, Tsuyoshi Takahashi, Mikio Oka, Hisashi Wada, Hidetoshi Eguchi, Yuichiro Doki
-
Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway Br. J. Cancer (IF 8.8) Pub Date : 2024-02-05 Jun Yang
-
Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus Br. J. Cancer (IF 8.8) Pub Date : 2024-02-05 Masashi Hashimoto, Shinji Kuroda, Nobuhiko Kanaya, Daisuke Kadowaki, Yusuke Yoshida, Masaki Sakamoto, Yuki Hamada, Ryoma Sugimoto, Chiaki Yagi, Tomoko Ohtani, Kento Kumon, Yoshihiko Kakiuchi, Kazuya Yasui, Satoru Kikuchi, Ryuichi Yoshida, Hiroshi Tazawa, Shunsuke Kagawa, Takahito Yagi, Yasuo Urata, Toshiyoshi Fujiwara
-
Antibodies toward Na+,HCO3–-cotransporter NBCn1/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-02-03 Trine V. Axelsen, Claus Olesen, Danish Khan, Ali Mohammadi, Elena V. Bouzinova, Christine J. F. Nielsen, Marco Mele, Katrine R. Hauerslev, Helene L. Pedersen, Eva Balling, Pernille Vahl, Trine Tramm, Peer M. Christiansen, Ebbe Boedtkjer
-
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer Br. J. Cancer (IF 8.8) Pub Date : 2024-02-02 Simon Holt, Mark Verrill, Laura Pettit, Anna Rigg, Tamas Hickish, Caroline Archer, Jo Dent, Marianne Dillon, Mark Nathan, Ludger Barthelmes, Shazza Rehman, Yousef Sharaiha, Paige Innis, Priya Sai-Giridhar, Saira Khawaja
-
Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8+ T cell infiltration Br. J. Cancer (IF 8.8) Pub Date : 2024-01-30 Masaya Kanahori, Eijiro Shimada, Yoshihiro Matsumoto, Makoto Endo, Toshifumi Fujiwara, Akira Nabeshima, Takeshi Hirose, Kengo Kawaguchi, Ryunosuke Oyama, Yoshinao Oda, Yasuharu Nakashima
-
Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells Br. J. Cancer (IF 8.8) Pub Date : 2024-01-29 Esha T. Shah, Christopher Molloy, Madeline Gough, Thomas Kryza, Selwin G. Samuel, Amos Tucker, Maneet Bhatia, Genevieve Ferguson, Rebecca Heyman, Shivam Vora, James Monkman, Emma Bolderson, Arutha Kulasinghe, Yaowu He, Brian Gabrielli, John D. Hooper, Derek J. Richard, Kenneth J. O’Byrne, Mark N. Adams
-
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours Br. J. Cancer (IF 8.8) Pub Date : 2024-01-29 Howard A. Burris, Jordan Berlin, Tobias Arkenau, Gregory M. Cote, Martijn P. Lolkema, Jordi Ferrer-Playan, Anup Kalapur, Jayaprakasam Bolleddula, Giuseppe Locatelli, Thomas Goddemeier, Ioannis Gounaris, Johann de Bono
-
Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma Br. J. Cancer (IF 8.8) Pub Date : 2024-01-27 Wanzun Lin, Xiaochuan Chen, Zongwei Huang, Qin Ding, Hanxuan Yang, Ying Li, Duo Lin, Jun Lin, Haojiong Zhang, Xuelian Yang, Chao Li, Chuanben Chen, Sufang Qiu
-
Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma Br. J. Cancer (IF 8.8) Pub Date : 2024-01-26 Eun Ju Cho, Boram Kim, Su Jong Yu, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Jung-Hwan Yoon, Taesung Park
-
Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib Br. J. Cancer (IF 8.8) Pub Date : 2024-01-27 Thomas Gaillard, Jeanne Piketty, Jean-Guillaume Feron, Noemie Girard, Lea Pauly, Elodie Gauroy, Lauren Darrigues, Beatriz Grandal, Jean-Yves Pierga, Anne-Sophie Hamy-Petit, Fabien Reyal, Enora Laas
-
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors Br. J. Cancer (IF 8.8) Pub Date : 2024-01-26 Marcell Baranyi, Eszter Molnár, Luca Hegedűs, Zsófia Gábriel, Flóra Gréta Petényi, Fanni Bordás, Violetta Léner, Ivan Ranđelović, Mihály Cserepes, József Tóvári, Balázs Hegedűs, József Tímár